课题基金 / 基金详情

Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications

Discovery of alpha4beta2 Nicotinic Receptor Antagonists as Alcohol Abuse Medications
发现 α4β2 烟碱受体拮抗剂作为酒精滥用药物
批准号:
9202126
负责人:
LAWRENCE R TOLL
金额:
$22.5万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-25 至 2018-09-30

项目摘要

项目成果

LAWRENCE R TOLL的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结
英文摘要
PROJECT SUMMARY Alcohol addiction and disorders associated to excessive alcohol use are a serious public health problem in the United States and in other parts of the world. Current pharmacotherapies for the treatment of these disorders show limited efficacy. Preclinical and clinical findings point to nicotinic acetylcholine receptors (nAChRs) as an alternative, promising target for the development of novel and effective medications. However, it is unclear which specific nAChR subtypes serve as mediators of the rewarding effects of alcohol due, in part, to the complexity of the different possible combinations of the subunits that compose nAChRs and the lack of potent and selective ligands. Using combinatorial libraries, scaffold ranking and position scanning strategies, Assuage Pharmaceuticals, in collaboration with Torrey Pines Institute for Molecular Studies has discovered new scaffolds that have produced high affinity nAChR antagonists with exquisite selectivity for 42 nAChRs over 34 nAChRs, with respect to both binding affinity and in vitro functional activity. When tested in rats, one lead compound, TPI-202 as well as varenicline (a partial agonist of 42 nAChRs), but not 34 nAChR directed ligands, attenuated both alcohol- and nicotine-taking behaviors in a paradigm in which the two reinforcers were concurrently available. The 34 nAChR directed ligands were only effective in reducing nicotine self- administration. These initial findings led us to hypothesize that 42 nAChRs may serve as a viable target for developing pharmacotherapies to treat alcohol dependence. To verify this hypothesis, here we propose to use the Assuage compounds to examine whether novel, high affinity and selective 42 nAChR antagonists are effective in reducing important aspects of alcohol addiction including excessive alcohol intake and vulnerability to relapse. To accomplish this objective two specific aims have been proposed. The purpose of Specific Aim 1 is to (A) re-synthesize selective 42 nAChR compounds (TPI-202, -211, -412, and -421) and (B) determine in vitro functional activities prior to in vivo testing. Specific Aim 2 is aimed at testing the in vivo efficacy of these compounds. It will determine whether the selective 42 antagonists block (A) both operant and excessive home cage alcohol drinking and (B) relapse into alcohol seeking as assessed by both cue-induced and stress- induced reinstatement paradigms. We expect this multidisciplinary proposal to identify novel pharmacological tools that can be optimized in a future Phase II application, and ultimately to be used as medications for excessive alcohol use and dependence.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA
  • 批准号:
    9552765
  • 项目类别:
  • 资助金额:
    $45.33万
  • 财政年份:
    2018
  • 负责人:
    LAWRENCE R TOLL
  • 依托单位:
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA
  • 批准号:
    9980820
  • 项目类别:
  • 资助金额:
    $45.29万
  • 财政年份:
    2018
  • 负责人:
    LAWRENCE R TOLL
  • 依托单位:
MIXED NOP/MU COMPOUNDS AND THE INVOLVEMENT OF THEIR RECEPTORS IN ANALGESIA
  • 批准号:
    10199982
  • 项目类别:
  • 资助金额:
    $45.24万
  • 财政年份:
    2018
  • 负责人:
    LAWRENCE R TOLL
  • 依托单位:
Mixed NOP/mu Compounds and the Involvement of their Receptors in Analgesia
国内基金
海外基金
Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    乔安娜
  • 依托单位: